64 results about "Overweight" patented technology

Disclosed herein are methods for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity using a glucagon-like peptide-1 (GLP-1) receptor non-peptide agonist (NPA) compound selected from Compound 1, Compound 1a, Compound 2, Compound 3, pharmaceutically acceptable salts thereof, and hydrates of the compounds and pharmaceutically acceptable salts, by oral administration to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA. Also disclosed herein are uses of a GLP-1 receptor NPA compound for the manufacture of a medicament for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA.

The invention discloses cubilose mixing and canning equipment with an automatic batching function, and relates to the technical field of cubilose mixing and canning, and the cubilose mixing and canning equipment comprises a conveying belt on which a container for accommodating cubilose is borne and conveyed; the two weighing plates are hinged to the batching cylinder in a split rotating manner; the weighing plate has a measurement function, a low-weight / overweight discharge function and a standard discharge function; re-weighing is carried out through the arranged weighing panel and the sensor to determine whether the weight of the ingredients discharged by the quantifying device is a standard value or not, whether the weight of the ingredients is overweight or not is judged to be unqualified, at the moment, the weighing plate rotates upwards, meanwhile, the side discharging opening is opened, the overweight / low-weight ingredients are discharged from the side discharging opening, and then the ingredients are discharged. When the weight detected by the weighing plates is the standard weight, the motor drives the transmission shaft to rotate, the limiting plate continues to descend, the weighing plates rotate downwards, the opening and closing baffle slowly retracts into the weighing plates, a discharging opening is formed between the two weighing plates / the opening and closing baffle, and ingredients fall down from the opening.

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention relates to methods for treating overweight or obese in individuals in need thereof, and / or individuals with fatty liver disease or diabetes. In particular, the present invention relates to a method of treating obesity, fatty liver disease or diabetes in an individual in need thereof, the method comprising administering a SIK-3 inhibitor and a metabolic modulator to the individual.

The invention discloses a child overweight and obesity detection method and system based on multi-index cooperative determination, and the method comprises the steps: firstly deploying and initializing a special multi-mode detection tool, and inputting the basic information of a child; and then guiding the integrated device and the portable module for children to acquire physique indexes according to prompts, calling intelligent wearing behavior data, verifying the intelligent wearing behavior data, and storing the intelligent wearing behavior data into a local database of the terminal. Extracting multi-modal data, importing the multi-modal data into a built-in model, matching a WHO standard and a metabolic reference range according to age and gender, assigning differential weights according to growth stages, and correcting and outputting an obesity trend probability basic value in combination with a growth rate. The behavior data is quantified, a risk matrix is established, a cause is positioned, then a report result containing obesity probability, influence factors and early warning levels is generated through integration, and suggestions are given to abnormal children on site. And effective intervention of overweight and obesity of children is facilitated.

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

Disclosed herein are combinations comprising an GLP-1R agonist and an inhibitor of menin. Also described are combinations of specific GLP-1R agonists and irreversible inhibitors or reversible inhibitors of menin. Also described are methods of using the combinations for the treatment of diabetes, obesity and overweight condition.

The present invention relates to the prevention and / or treatment of metabolic disorders such as overweight and obesity, and complications associated therewith. More specifically, the present invention relates to the bacterium Turicimonas muris or a fragment thereof for preventing and / or treating metabolic disorders and complications associated therewith.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist, with an optimized GLP-1R agonist / FGF21 compound activity ratio. The present invention also relates to the use of said combinations, pharmaceutical compositions and fusion molecules as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.

Provided are GIPR and GLP-1R co-agonistic polypeptides, or pharmaceutically acceptable salts, amides or esters thereof, and uses of the polypeptides, salts, amides or esters, including treatment of type II diabetes, obesity, overweight, and the like.

The invention relates to a compound comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to a pharmaceutical formulation, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical formulation comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

Methods of treating a subject having a metabolic syndrome or disease, diabetes, obesity, overweight, eating disorders, polyphagia, hyperlipidemia, insulin resistance, or methods of reducing body weight in a subject are provided. The methods involve administering to the subject a composition comprising a compound of formula I, including, for example, GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6- or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer, stereoisomer, tautomer or isotope variant thereof, and a pharmaceutically acceptable carrier or excipient.

The application discloses a traditional Chinese medicine composition for people with obesity and overweight of spleen deficiency and damp-heat type and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: Gualou 40-60 parts, Yiyiren 30-50 parts, Fuling 80-110 parts, Zhizi 10-20 parts, Renshen 1-5 parts and Huangjing 5-10 parts. The Gualou, Yiyiren and Fuling are used as monarch drugs to invigorate the spleen and eliminate dampness, the Zhizi is used as a minister drug to clear heat and drain dampness, the Renshen and Huangjing are used to tonify qi and nourish yin, support the root of spleen deficiency, and make up for the bitter cold of the Zhizi to hurt the stomach, so that the traditional Chinese medicine composition can achieve the functions of invigorating the spleen and eliminating dampness, clearing heat and tonifying qi, and treat the root and branch of the people with obesity and overweight of spleen deficiency and damp-heat type according to the pathogenesis characteristics of the spleen deficiency as the root and the damp-heat as the branch. The application has a simple formula, mild medicinal properties, and is suitable for long-term taking. The application further provides a preparation method of the traditional Chinese medicine composition, which can be prepared into a decoction, granules, capsules, tablets, pills or oral liquid, and has the advantages of simple preparation process, stable product quality and convenient taking.

The present disclosure provides ALK7 binding proteins, such as anti-ALK7 antibodies and compositions, and methods for making the same. In certain embodiments, the ALK7 binding proteins inhibit or antagonize ALK7 activity. Further, the present disclosure provides compositions and methods for diagnosing and treating the following diseases: overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and associated conditions thereof; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.

The present disclosure provides methods of treating overweight or obese patients with or without type 2 diabetes mellitus. The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.

The present disclosure relates to a polypeptide analog or a derivative thereof, and a preparation method and use thereof, and particularly to an agonistic polypeptide analog or a derivative thereof of an insulin amyloid polypeptide receptor. The polypeptide analog or the derivative thereof provided by the present disclosure has good agonistic activity on the insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity, etc. at the same time, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as body weight abnormality, especially obesity and overweight.

Provided are a GIPR and GLP-1R dual agonist polypeptide, or a pharmaceutically acceptable salt, amide or ester thereof, and a use of the polypeptide, salt, amide or ester, comprising treating type II diabetes, obesity, overweight, etc.

Disclosed herein are novel modulators for GIPR, GLP-1R and / or GCGR. Specifically, provided herein are antibodies that specifically bind GIPR, oxyntomodulin analog peptides, and antibody- peptide conjugates (APCs) comprising an anti-GIPR antibody and an agonist for GLP-1R and / or GCGR (e.g., oxyntomodulin analog). Pharmaceutical compositions comprising these modulators disclosed herein, as well as uses thereof in treating metabolic conditions and disorders, such as diabetes (e.g., type 2 diabetes), NASH, overweight, and obesity are also provided.

The present invention relates to a compound comprising an amylin receptor agonist.The present invention also relates to a pharmaceutical composition comprising such a compound, suitable for oral administration, but not limited thereto.The compound and the pharmaceutical composition comprising it can be used for the medical treatment of subjects with overweight, obesity and related comorbidities.

Provided are GIPR and GLP-1R co-agonist polypeptides, or pharmaceutically acceptable salts, amides or esters thereof, and uses of the above polypeptides, salts, amides or esters, including treating type II diabetes, obesity or overweight, etc.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention belongs to the field of medicine, and specifically relates to a treatment method using mazdutide. The present invention provides a method for preventing or treating overweight and obesity, and a method for improving body weight in patients in need, the method comprising administering, to a patient in need, a prophylactically or therapeutically effective amount of a target compound in a dosage regimen comprising at least three dosing cycles. The present invention also provides a target compound, which is used for preventing or treating overweight or obesity in patients in need, wherein a prophylactically or therapeutically effective amount of the target compound is administered in at least three dosing cycles to a patient in need. The mazdutide dosage regimen provided has a remarkable weight reduction effect, noticeable weight reduction can be achieved with relatively low dosage in a relatively short amount of time, and blood pressure, blood lipid, and serum uric acid levels of a subject can simultaneously be improved.

Disclosed herein is a preserved liquid pharmaceutical formulation comprising a amylin receptor agonist, a GLP-1 receptor agonist, a hydroxypropyl-substituted cyclodextrin, and one or more preservatives. The co-formulation can be used for medical treatment of subjects with: overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated co-morbidities; and cardiovascular disease.

Disclosed herein are novel modulators of GIPR, GLP-1R, and / or GCGR. In particular, provided herein are antibodies, oxyntomodulin analogue peptides, and antibody-peptide conjugates (APC) that specifically bind to GIPR, the antibody-peptide conjugates comprising an anti-GIPR antibody and an agonist of GLP-1R and / or GCGR (e.g., oxyntomodulin analogue). Also provided are pharmaceutical compositions comprising these modulators disclosed herein, and the use of the pharmaceutical compositions in the treatment of metabolic conditions and disorders, such as diabetes (e.g., type 2 diabetes), NASH, overweight, and obesity.

To provide fusion proteins with optimized GLP-1R agonist / FGF21 compound activity ratio.SOLUTION: The invention relates to a fusion protein comprising a glucagon-like peptide 1 receptor 5 (GLP-1R) agonistic peptide and a variant of human fibroblast growth factor 21 (FGF21). The invention further relates, in particular to the use of a fusion protein comprising a GLP-1R agonistic peptide and a variant of FGF21 as a medicament for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyper glycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis in a subject. The invention further relates to pharmaceutical compositions comprising a fusion protein comprising a GLP-1R agonistic peptide and a variant of FGF21.SELECTED DRAWING: None

The disclosure relates to the prevention or treatment of overweight or obesity. The disclosure also relates to non-human mammals resistant to overweight or obesity, methods of producing said non-human mammals, methods of determining the relevance of a gene to obesity, and methods for selecting an agent for use in the prevention or treatment of overweight or obesity.

This invention relates to the field of functional food technology, specifically to a solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects, and its preparation method. The solid beverage comprises the following ingredients by weight: 2-3 parts modified sodium alginate, 5-8 parts inulin, 2-4 parts orange peel, 3-6 parts red adzuki bean extract, 1.5-3 parts cassia seed extract, 1-2 parts bitter orange flower extract, 2-4 parts radish seed extract, 3-6 parts hawthorn, and 2-4 parts lotus leaf extract. This solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects has the functions of lowering lipids, promoting digestion, weight loss, and spleen strengthening. Combined with dietary fiber such as inulin and resistant dextrin, it helps maintain intestinal function. Modified sodium alginate improves emulsification and dissolving stability. This solid beverage can be used as an auxiliary conditioning drink for overweight and hyperlipidemic individuals.